Baseline characteristics of the entire cohort (N = 35)
Characteristic . | Value . |
---|---|
Age, median (range), y | 67 (38-78) |
Male | 24 (69%) |
Race, white | 35 (100%) |
ECOG performance status score | |
0 | 16 (46%) |
1 | 17 (49%) |
2 | 2 (6%) |
Eligible for autologous stem cell transplant | 29 (85%) |
Involved organs | |
Cardiac | 23 (66%) |
Renal | 19 (54%) |
Nerve | 6 (17%) |
Hepatic | 4 (11%) |
>1 organ | 15 (43%) |
Lambda restricted | 26 (74%) |
BMPCs, median (range), % | 9 (<5%-30%) |
dFLC, median (range), mg/dL | 29.0 (5.0-109) |
Serum creatinine, median (range), mg/dL | 1.1 (0.6-1.9) |
2012 Mayo AL amyloidosis stage, I/II/III/IV, % | 20/31.4/22.9/25.7 |
FISH abnormalities (n = 28)* | |
t(11;14) | 50% |
del(13q)/monosomy 13 | 43% |
Trisomies | 32% |
gain(1q) | 14% |
del(17p)/monosomy 17 | 11% |
t(4;14) | 4% |
t(14;20) | 4% |
>1 abnormality | 61% |
Characteristic . | Value . |
---|---|
Age, median (range), y | 67 (38-78) |
Male | 24 (69%) |
Race, white | 35 (100%) |
ECOG performance status score | |
0 | 16 (46%) |
1 | 17 (49%) |
2 | 2 (6%) |
Eligible for autologous stem cell transplant | 29 (85%) |
Involved organs | |
Cardiac | 23 (66%) |
Renal | 19 (54%) |
Nerve | 6 (17%) |
Hepatic | 4 (11%) |
>1 organ | 15 (43%) |
Lambda restricted | 26 (74%) |
BMPCs, median (range), % | 9 (<5%-30%) |
dFLC, median (range), mg/dL | 29.0 (5.0-109) |
Serum creatinine, median (range), mg/dL | 1.1 (0.6-1.9) |
2012 Mayo AL amyloidosis stage, I/II/III/IV, % | 20/31.4/22.9/25.7 |
FISH abnormalities (n = 28)* | |
t(11;14) | 50% |
del(13q)/monosomy 13 | 43% |
Trisomies | 32% |
gain(1q) | 14% |
del(17p)/monosomy 17 | 11% |
t(4;14) | 4% |
t(14;20) | 4% |
>1 abnormality | 61% |
BMPC, bone marrow plasma cells; dFLC, difference between involved to uninvolved light chains; ECOG, Eastern Cooperative Oncology Group.
Four patients had insufficient clonal plasma cells for testing; 3 patients did not have fluorescence in situ hybridization (FISH) testing performed.